

FOR IMMEDIATE RELEASE

ImQuest Pharmaceuticals announces the appointment of David Ho, M.D. to its Scientific Advisory Board.

ImQuest Pharmaceuticals, Inc. announced today the appointment of David Ho, M.D. to its Scientific Advisory Board.

David D. Ho, M.D. is the founding Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center, a world-renowned biomedical research institute. He is also the Irene Diamond Professor at The Rockefeller University. Dr. Ho received his degrees from California Institute of Technology (1974) and Harvard Medical School (1978). Subsequently, he did his clinical training in internal medicine and infectious diseases at Cedars-Sinai Medical Center/UCLA School of Medicine and Massachusetts General Hospital/Harvard Medical School, respectively. Dr. Ho has been at the forefront of AIDS research for 26 years, publishing over 350 papers. Dr. Ho performed pioneering studies on the dynamics of HIV replication and combination antiretroviral therapy, which resulted in unprecedented control of HIV in patients. Dr. Ho's research team is now devoting considerable efforts to develop vaccines to halt the spread of the AIDS epidemic and he heads a consortium of Chinese and American organizations to help address the crisis of HIV/AIDS in China. Dr. Ho has received numerous honors and awards for his scientific accomplishments. He is the recipient of nine honorary doctorates, the Ernst Jung Prize in Medicine, the Mayor's Award for Excellence in Science & Technology, the Squibb Award, and the Hoechst Marion Roussel Award. Dr. Ho has been elected as a member of the American Academy of Arts and Sciences, Academia Sinica (Republic of China), Chinese Academy of Engineering, and the Institute of Medicine, National Academy of Science in the United States. He was a member of the Board of Overseers of Harvard University and the Board of Trustees of the California Institute of Technology and is currently a board member of the Massachusetts Institute of Technology Corporation. Dr. Ho was named Time Magazine's Man of the Year in 1996, and was the recipient of a Presidential Medal in 2001.

Commenting on the appointment, ImQuest's CSO, Dr. Robert W. Buckheit, Jr. said, "We are honored to have Dr. David Ho as a member of our Scientific Advisory Board at ImQuest and to have access to his expertise in HIV replication and antiretroviral therapy to assist with our development of novel therapeutic agents for the treatment of HIV infection. Dr. Ho will be instrumental to the development of our first HIV drug candidate (IQP-0410) to the clinic, as well as assisting us to further develop our diversified portfolio of highly active HIV therapeutics and microbicides."

ImQuest Pharmaceuticals, Inc. is a privately held U.S. company located in Frederick, Maryland that specializes in the development of novel, "first-in-class" compounds for the treatment of infectious disease and cancer. Information on ImQuest's therapeutic products and corporate development strategy can be found at www.imquestpharma.com.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Chief Scientific Officer

ImQuest Pharmaceuticals, Inc.

301-696-0274

rbuckheit@imquest.com